{"product_id":"cvm-vrio-analysis","title":"CEL-SCI Corporation (CVM): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlocking the sustainable competitive edge for CEL-SCI Corporation (CVM) hinges on a rigorous VRIO analysis, which we've distilled into key insights regarding its Value, Rarity, Inimitability, and Organization. Discover immediately which core capabilities truly set this business apart and which areas require strategic focus to maintain market leadership. Dive into the full breakdown below to see the complete picture.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eCEL-SCI Corporation (CVM) - VRIO Analysis: \u003cstrong\u003e1. Multikine Phase III Efficacy Data Set\u003c\/strong\u003e\n\u003c\/h2\u003e\n\n\u003cp\u003eYou're looking at the core asset for CEL-SCI Corporation (CVM): the efficacy data for Multikine in head and neck cancer. Honestly, this data set is what drives the entire near-term valuation narrative for the company. The key takeaway is the statistically significant survival benefit seen in a specific, large patient subset.\u003c\/p\u003e\n\n\u003ch3\u003eValue: Survival Benefit in Low PD-L1 Population\u003c\/h3\u003e\n\u003cp\u003eThe data provides statistically significant evidence of improved 5-year Overall Survival (OS) in the targeted head and neck cancer patient group - those with low (TPS \u0026lt;10) PD-L1 expression. In the prior Phase 3 randomized controlled study involving 928 patients, this specific group saw a 5-year survival rate of 73% when treated with Multikine before surgery and radiation, compared to only 45% for the control group receiving standard of care. This represents a massive 28 percentage point absolute advantage, with a log rank p-value of 0.0015 and a hazard ratio of 0.35. This is critical because this low PD-L1 population makes up about 70% of newly diagnosed locally advanced head and neck cancer patients, a group where current checkpoint inhibitors often don't work well. It’s a clear, hard number showing a potential new standard of care.\u003c\/p\u003e\n\n\u003cp\u003eHere’s the quick math on the historical Phase 3 result for this target group:\u003c\/p\u003e\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eMetric\u003c\/td\u003e\n    \u003ctd\u003eMultikine + SOC\u003c\/td\u003e\n    \u003ctd\u003eControl (SOC Only)\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e5-Year Overall Survival\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e73%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e45%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003ePatient Count (Retrospective Subgroup)\u003c\/td\u003e\n    \u003ctd\u003eNot explicitly stated, but part of N=928 trial\u003c\/td\u003e\n    \u003ctd\u003eNot explicitly stated, but part of N=928 trial\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eLog Rank p-value\u003c\/td\u003e\n    \u003ctd colspan=\"2\"\u003e\u003cstrong\u003e0.0015\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eHazard Ratio (HR)\u003c\/td\u003e\n    \u003ctd colspan=\"2\"\u003e\u003cstrong\u003e0.35\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eRarity: Scale and Specificity\u003c\/h3\u003e\n\u003cp\u003eThe rarity here isn't just the survival magnitude, but achieving it within a Phase 3 trial of 928 patients for a company of CEL-SCI Corporation's current size. While other companies have immunotherapy data, showing this level of benefit in the PD-L1 low subset is unique for a first-line, neoadjuvant approach. What this estimate hides is that the data is retrospective from the initial Phase 3, which is why the 212-patient confirmatory study is so vital to prospectively validate this finding.\u003c\/p\u003e\n\n\u003ch3\u003eImitability: Mechanism vs. Data Ownership\u003c\/h3\u003e\n\u003cp\u003eThe raw, statistically significant data set itself is owned by CEL-SCI Corporation; you can't replicate that historical trial outcome. However, the underlying concept - boosting the immune system before standard-of-care - is conceptually imitable by other immunotherapy developers. The specific formulation and mechanism of action for Multikine are proprietary, but the general field of immuno-oncology is crowded. The true barrier to imitation is the time and capital required to run a similar, large-scale trial to prove the effect, which CEL-SCI Corporation has already done.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization: Focus on Regulatory Validation\u003c\/h3\u003e\n\u003cp\u003eThe company is defintely organized around exploiting this data, which is the only path to commercialization right now. You see this focus clearly in their recent actions and capital structure. They secured FDA concurrence to use the PD-L1 biomarker for patient selection in the final confirmatory trial. This is a huge organizational win, simplifying the path forward.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCommenced 212-patient confirmatory Registration Study in Q1 2025.\u003c\/li\u003e\n\u003cli\u003eCEO Geert Kersten is working without a salary to preserve capital.\u003c\/li\u003e\n\u003cli\u003eRaised approximately $5.7 million in July 2025 and $5 million in May 2025 via stock offerings.\u003c\/li\u003e\n\u003cli\u003eManufacturing facility has capacity for over 12,000 treatments annually, with over $200 million invested in its development.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eCompetitive Advantage: Temporary\u003c\/h3\u003e\n\u003cp\u003eThe current advantage is \u003cstrong\u003eTemporary\u003c\/strong\u003e. It is entirely contingent on the successful outcome of the ongoing 212-patient confirmatory Registration Study and subsequent regulatory approval. If CEL-SCI Corporation secures approval, the advantage becomes much stronger, potentially sustained due to the unique mechanism targeting the 70% of patients missed by current market leaders. If the confirmatory trial fails to meet its endpoints, the historical data becomes a historical footnote, and the advantage evaporates. If onboarding for the new trial takes longer than expected, churn risk for potential partners rises.\u003c\/p\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eCEL-SCI Corporation (CVM) - VRIO Analysis: \u003cstrong\u003e2. Proprietary Low PD-L1 Patient Selection Strategy\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAllows CEL-SCI Corporation to target an estimated \u003cstrong\u003e70%\u003c\/strong\u003e of head and neck cancer patients who may not respond well to standard checkpoint inhibitors, creating a unique market niche.\u003c\/li\u003e\n\u003cli\u003eIn the prior randomized controlled Phase 3 study, patients with low PD-L1 expression treated with Multikine in the target population had a 5-year survival of \u003cstrong\u003e73%\u003c\/strong\u003e versus \u003cstrong\u003e45%\u003c\/strong\u003e in the control group.\u003c\/li\u003e\n\u003cli\u003eIn the completed Phase 3 study, Multikine treated patients whose tumors expressed low (Tumor Proportion Score [TPS \u0026lt;10]) to zero PD-L1, had their risk of death reduced by \u003cstrong\u003e66%\u003c\/strong\u003e (hazard ratio \u003cstrong\u003e0.34\u003c\/strong\u003e, 95% CI [0.18, 0.65], p=\u003cstrong\u003e0.0012\u003c\/strong\u003e) and extended the 5-year overall survival to \u003cstrong\u003e73%\u003c\/strong\u003e compared to \u003cstrong\u003e45%\u003c\/strong\u003e in the standard of care, log rank p=\u003cstrong\u003e0.0015\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThis inverse correlation (better response with low PD-L1) is rare, as many competitors target high PD-L1 expression.\u003c\/li\u003e\n\u003cli\u003eCheckpoint inhibitors such as nivolumab (Opdivo) and pembrolizumab (Keytruda) appear to work best for patients with high PD-L1 expression.\u003c\/li\u003e\n\u003cli\u003eThe global PD-L1\/PD-1 therapeutics market was valued at \u003cstrong\u003e$34.8 billion\u003c\/strong\u003e in 2022.\u003c\/li\u003e\n\u003cli\u003eKeytruda, a leading checkpoint inhibitor, had an estimated 2024 sales of \u003cstrong\u003e$27 billion\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe specific biomarker-efficacy link derived from their trial is difficult to replicate without running a similar, large-scale trial.\u003c\/li\u003e\n\u003cli\u003eCEL-SCI has filed a patent for the use of Multikine in tumors expressing low levels of PD-L1.\u003c\/li\u003e\n\u003cli\u003eThe company's manufacturing facility has the capacity to produce over \u003cstrong\u003e12,000\u003c\/strong\u003e Multikine treatments per year, with over \u003cstrong\u003e$200 million\u003c\/strong\u003e invested in the facility and proprietary biologic manufacturing processes.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe FDA concurred with using PD-L1 as a biomarker for the final Registration Study, showing regulatory alignment.\u003c\/li\u003e\n\u003cli\u003eThe confirmatory Registration Study is slated to commence in the first quarter of 2025 and will enroll approximately \u003cstrong\u003e212\u003c\/strong\u003e patients.\u003c\/li\u003e\n\u003cli\u003eThe prior Phase 3 study enrolled \u003cstrong\u003e928\u003c\/strong\u003e patients.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSustained, if approved. This positions Multikine as a first-in-class option for a large, underserved patient segment.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eMultikine (Low PD-L1 Subgroup)\u003c\/th\u003e\n\u003cth\u003eStandard of Care (Control Group)\u003c\/th\u003e\n\u003cth\u003eCheckpoint Inhibitors (High PD-L1)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e5-Year Survival Rate\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e73%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e45%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNot specified for OS in this context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRisk of Death Reduction (vs. SOC)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e66%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStatistical Significance (Log Rank)\u003c\/td\u003e\n\u003ctd\u003ep=\u003cstrong\u003e0.0015\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget Patient Segment Size (H\u0026amp;N)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e70%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eThe remaining population\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eCEL-SCI Corporation's market capitalization was \u003cstrong\u003e$47.78 million\u003c\/strong\u003e, with \u003cstrong\u003e8.02 million\u003c\/strong\u003e shares outstanding as of a recent report.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eCEL-SCI Corporation (CVM) - VRIO Analysis: \u003cstrong\u003e3. Multikine Biologic Manufacturing Facility\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\nValue: Owns a 76,785 square foot facility in Baltimore, MD, which underwent an additional $10.7 million to $11 million investment in 2021 to expand and upgrade manufacturing capabilities to current GMP standards. The initial acquisition and redevelopment cost was approximately $22M. The facility's production capacity was \u003cstrong\u003edoubled\u003c\/strong\u003e following the 2021 expansion.\n\u003c\/p\u003e\n\u003cp\u003e\nRarity: Owning and validating a dedicated, large-scale cGMP facility for a complex biologic is rare for a clinical-stage company; most outsource production. The facility's commissioning was substantially complete as of October 2023, supporting a planned Biologics License Application (BLA).\n\u003c\/p\u003e\n\u003cp\u003e\nImitability: High. Replicating the physical plant and the validated, proprietary manufacturing know-how requires significant time and capital, including the sunk cost of the initial $22M plus subsequent upgrades.\n\u003c\/p\u003e\n\u003cp\u003e\nOrganization: The company is prepared to supply the market, as evidenced by the stated capacity increase and the facility being prepared for commercial distribution upon BLA approval. The manufacturing supported the largest clinical trial of its primary indication, which involved 928 patients.\n\u003c\/p\u003e\n\u003cp\u003e\nCompetitive Advantage: Sustained. This sunk cost and validated process provide a significant barrier to entry for a new competitor needing to scale up quickly.\n\u003c\/p\u003e\n\u003cp\u003e\nFacility Details:\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\nFacility Size: \u003cstrong\u003e76,785\u003c\/strong\u003e square feet.\n\u003c\/li\u003e\n\u003cli\u003e\nRecent Capital Investment for Expansion\/Upgrades: Approximately $11 million in 2021.\n\u003c\/li\u003e\n\u003cli\u003e\nInitial Acquisition\/Redevelopment Cost: Approximately $22 million.\n\u003c\/li\u003e\n\u003cli\u003e\nCapacity Status: Production capacity was \u003cstrong\u003edoubled\u003c\/strong\u003e in 2021.\n\u003c\/li\u003e\n\u003cli\u003e\nOperational Milestone: Facility commissioning substantially complete as of October 2023.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\nSupporting Financial\/Operational Context:\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eReference\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 3 Trial Enrollment\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e928\u003c\/strong\u003e Patients\u003c\/td\u003e\n\u003ctd\u003eLargest clinical trial ever done for head and neck cancer.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFacility Investment (2021)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$10.7 million\u003c\/strong\u003e to \u003cstrong\u003e$11 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eFor expansion and bringing manufacturing areas up to 'current' GMP standards.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFacility Type\u003c\/td\u003e\n\u003ctd\u003eDedicated cGMP\u003c\/td\u003e\n\u003ctd\u003eFor Multikine production.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eCEL-SCI Corporation (CVM) - VRIO Analysis: \u003cstrong\u003e4. LEAPS Technology Platform\u003c\/strong\u003e\n\u003c\/h2\u003e\n\n\u003cp\u003eThe LEAPS (Ligand Epitope Antigen Presentation System) technology represents a distinct, secondary platform to the lead Multikine asset.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides a platform for developing therapies beyond Multikine, targeting Rheumatoid Arthritis, other autoimmune, and infectious diseases, diversifying future revenue streams. The potential addressable US market for Multikine is cited at approximately 145,000 eligible patients annually in its tested group, making diversification via LEAPS critical for long-term value.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e It represents a distinct, early-stage technology platform separate from their lead cancer asset. The LEAPS technology for rheumatoid arthritis is supported by grants from the National Institutes of Health.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. The underlying science is likely protected, but the platform's success is unproven compared to Multikine. The platform is currently in the preclinical trial phase for applications including rheumatoid arthritis and infectious diseases.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The company mentions LEAPS progress at investor events, showing it is on the radar, though secondary to Multikine. The organization's capacity to advance LEAPS is framed by its overall financial structure and resource allocation.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eContext\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLEAPS Development Stage\u003c\/td\u003e\n\u003ctd\u003ePreclinical Trial Phase\u003c\/td\u003e\n\u003ctd\u003eFor Rheumatoid Arthritis, Autoimmune, Infectious Diseases\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExternal Funding Support\u003c\/td\u003e\n\u003ctd\u003eNIH Grants\u003c\/td\u003e\n\u003ctd\u003eFor Rheumatoid Arthritis Vaccine development\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss (Fiscal Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eRepresents cash burn funding R\u0026amp;D, including LEAPS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Proceeds Raised (May\/Jul 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCapital infusion to fund operations\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFull-Time Employees\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e43\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCompany size supporting R\u0026amp;D efforts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. It’s an option value; its advantage is only realized if the platform yields a successful second product.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eCEL-SCI Corporation (CVM) - VRIO Analysis: \u003cstrong\u003e5. Progress in Saudi Arabia Regulatory Pathway\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003eThe progress in the Saudi Arabia regulatory pathway is characterized by specific timelines, partnership execution, and alignment with national strategic goals.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\/Detail\u003c\/th\u003e\n\u003cth\u003eSource\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSFDA Review Time for BMD\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e60 days\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eResponse time to Breakthrough Medicine Designation application.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePotential Commercial Access\u003c\/td\u003e\n\u003ctd\u003eImmediately available for patient access and reimbursement\/sale\u003c\/td\u003e\n\u003ctd\u003eFollowing the granting of Breakthrough Medicine Designation.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLocal Partner Status\u003c\/td\u003e\n\u003ctd\u003eCommercialization and regulatory partnership agreement set to be signed\u003c\/td\u003e\n\u003ctd\u003eFollowing a Memorandum of Understanding (MOU).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAlignment with Vision 2030\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eSeeks to make the Kingdom a global biotech hub.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMultikine 5-Year Survival Rate (Phase 3)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e73%\u003c\/strong\u003e vs \u003cstrong\u003e45%\u003c\/strong\u003e (Standard of Care)\u003c\/td\u003e\n\u003ctd\u003eClinical data supporting the designation filing.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e5-Year Risk of Death Reduction\u003c\/td\u003e\n\u003ctd\u003eHalved from \u003cstrong\u003e55%\u003c\/strong\u003e to \u003cstrong\u003e27%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eClinical data supporting the designation filing.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe VRIO components are detailed as follows:\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePotential for patient access and reimbursement\/sale in Saudi Arabia within approximately \u003cstrong\u003e60 days\u003c\/strong\u003e of designation approval.\u003c\/li\u003e\n\u003cli\u003eThe near-term Saudi market is estimated to contribute a significant \u003cstrong\u003e13%\u003c\/strong\u003e of the total estimated value.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSecuring a Breakthrough Medicine Designation filing with a clear, fast-track path to market in a major region is rare for a company awaiting US approval.\u003c\/li\u003e\n\u003cli\u003eThe SFDA response time is approximately \u003cstrong\u003e60 days\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThis is a unique regulatory achievement based on specific negotiations and data presentation in that jurisdiction.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company is actively pursuing this, with a formal partnership agreement expected to be signed.\u003c\/li\u003e\n\u003cli\u003eFinancial execution supporting operations included raising approximately \u003cstrong\u003e$5.7 million\u003c\/strong\u003e in July 2025 and \u003cstrong\u003e$5 million\u003c\/strong\u003e in May 2025.\u003c\/li\u003e\n\u003cli\u003eThe company extended its cash runway into the summer of \u003cstrong\u003e2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTemporary. This advantage is contingent on the designation being granted and the partnership closing successfully.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eCEL-SCI Corporation (CVM) - VRIO Analysis: \u003cstrong\u003e6. Management Commitment and Capital Efficiency\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e CEO Geert Kersten is working without a salary, demonstrating extreme commitment, which helps preserve cash runway for the critical final trial. This commitment was confirmed as of the reports dated May 15, 2025, and August 14, 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e A CEO working without salary is highly unusual and signals deep conviction in the asset's value.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. This is a specific, non-transferable commitment by a key individual.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e This commitment directly supports the company’s ability to fund operations, having raised approximately \u003cstrong\u003e$10.7 million\u003c\/strong\u003e in gross proceeds across two offerings in 2025. The company also executed a third major offering in August 2025.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eOffering Date (2025)\u003c\/th\u003e\n\u003cth\u003eGross Proceeds (Approx.)\u003c\/th\u003e\n\u003cth\u003eShares Sold\u003c\/th\u003e\n\u003cth\u003ePrice Per Share\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMay\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2,000,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.50\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJuly\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1,500,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.82\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAugust (Pricing)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1,111,200\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$9.00\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe commitment supports operations amidst ongoing financial needs, as evidenced by recent quarterly results and financial health indicators:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNet loss available to common shareholders for the three months ended June 30, 2025: \u003cstrong\u003e$5.7 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eBasic and diluted net loss per common share for the three months ended June 30, 2025: \u003cstrong\u003e$1.36\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet Income Trailing Twelve Months (TTM) as of June 30, 2025: \u003cstrong\u003e($25,420)\u003c\/strong\u003e in Thousands of USD.\u003c\/li\u003e\n\u003cli\u003eCurrent Ratio as of July 2025: \u003cstrong\u003e0.55\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNegative Free Cash Flow reported as nearly \u003cstrong\u003e$5 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. It buys time, but the underlying need for capital remains; it’s a stop-gap, not a permanent solution.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eCEL-SCI Corporation (CVM) - VRIO Analysis: \u003cstrong\u003e7. Completed Largest-Ever Head and Neck Cancer Phase III Trial\u003c\/strong\u003e\n\u003c\/h2\u003e\n\n\u003cp\u003eThe completed Phase III trial for Multikine in Head and Neck Cancer involved \u003cstrong\u003e78\u003c\/strong\u003e sites across \u003cstrong\u003e3\u003c\/strong\u003e continents.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Enrolled Patients (Phase III)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e928\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntent-to-Treat (ITT) Population\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e923\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e5-Year OS (Multikine + SOC vs. SOC Alone - Target Group)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e73%\u003c\/strong\u003e vs. \u003cstrong\u003e45%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAbsolute 5-Year OS Improvement (Target Group)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e28\u003c\/strong\u003e percentage points\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOverall Survival HR (Target Group without Chemo)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0.68\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOverall Survival HR (Low PD-L1 Group)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0.35\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStatistical Significance (Target Group without Chemo)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003ep=0.0236\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInvestment in Development\/Manufacturing\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e$200 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnual Manufacturing Capacity\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e12,000\u003c\/strong\u003e treatments\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eThe sheer size of the completed trial, enrolling \u003cstrong\u003e928\u003c\/strong\u003e patients, provides a level of statistical power and real-world data depth that smaller, newer trials cannot match. The 5-year overall survival rate for the target patient population increased to \u003cstrong\u003e73%\u003c\/strong\u003e when treated with Multikine versus \u003cstrong\u003e45%\u003c\/strong\u003e for control patients.\u003c\/p\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eIt is cited as the \u003cstrong\u003elargest\u003c\/strong\u003e Phase 3 study ever conducted in this indication, lending significant weight to the results. The trial demonstrated a statistically significant overall survival benefit of \u003cstrong\u003e14.1%\u003c\/strong\u003e at 5 years for the group receiving Multikine followed by surgery and radiotherapy but not chemotherapy.\u003c\/p\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eReplicating a trial of this scale (\u003cstrong\u003e928\u003c\/strong\u003e patients) and duration today would cost hundreds of millions and take years. The investment in development and proprietary biologic manufacturing processes is stated to be over \u003cstrong\u003e$200 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eThis historical investment is the foundation for all current regulatory and commercial strategy discussions. The FDA concurred with CEL-SCI's target patient selection criteria based on the completed Phase 3 study data. The company's manufacturing facility has the capacity to produce over \u003cstrong\u003e12,000\u003c\/strong\u003e Multikine treatments annually.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eGeneral and administrative expenses in fiscal 2024 were \u003cstrong\u003e$8.2 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet loss for the twelve months ended September 30, 2024, was approximately \u003cstrong\u003e$26.9 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eSustained. The historical investment and data set are a massive, non-replicable barrier to entry for a new competitor trying to prove efficacy from scratch. The target patient population (low PD-L1 expression) represents an estimated \u003cstrong\u003e70%\u003c\/strong\u003e of newly diagnosed locally advanced head and neck cancer patients who do not respond well to checkpoint inhibitors.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eCEL-SCI Corporation (CVM) - VRIO Analysis: \u003cstrong\u003e8. Expertise in Immunotherapy Mechanism of Action (MOA)\u003c\/strong\u003e\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eh\u003c\/strong\u003e\u003ch\u003eValue\u003c\/h\u003e\u003c\/p\u003e\n\u003cp\u003eDeep, specialized knowledge in using immunotherapy to boost the immune system before standard-of-care treatments damage immune function.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\nThe MOA suggests Multikine potentially signals the immune system to produce an anti-tumor immune response, changing the tumor microenvironment ratio of CD4\/DC8 cells from CD-8 cells to predominantly CD-4 cells.\n\u003c\/li\u003e\n\u003cli\u003e\nThe investigational therapy is administered locally, not systemically, in small supra physiological doses to avoid serious toxicities.\n\u003c\/li\u003e\n\u003cli\u003e\nPhase 3 study data showed that for the target population (no chemotherapy), the 5-year Overall Survival (OS) was 62.7% for the Multikine treatment regimen plus Surgery and Radiotherapy versus 48.6% for the control group.\n\u003c\/li\u003e\n\u003cli\u003e\nThe Phase 3 trial enrolled 928 patients.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eh\u003c\/strong\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003c\/p\u003e\n\u003cp\u003eWhile immunotherapy is common, CEL-SCI Corporation’s specific pre-treatment timing and mechanism are distinct from many checkpoint inhibitor approaches.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\nMultikine is administered prior to any other therapy because CEL-SCI believes this is the period when the anti-tumor immune response can be more fully activated, before surgery or radiation\/chemotherapy weaken the immune system.\n\u003c\/li\u003e\n\u003cli\u003e\nMultikine is the first investigational combination immunotherapy thought to have both passive and active immune properties.\n\u003c\/li\u003e\n\u003cli\u003e\nThe FDA accepted selection criteria for the confirmatory study based on the biological mechanism of action supported by the completed Phase 3 study.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eh\u003c\/strong\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003c\/p\u003e\n\u003cp\u003eModerate. The scientific understanding is codifiable, but the specific application is proprietary.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\nThe specific application is supported by clinical outcomes: the target population showed a 73% 5-year survival with Multikine vs. 45% for control.\n\u003c\/li\u003e\n\u003cli\u003e\nObjective Response Rate (ORR) within 3 weeks and before surgery for Multikine+CIZ patients in the lower-risk arm was 15.2% (24\/158) versus zero in the SOC group.\n\u003c\/li\u003e\n\u003cli\u003e\nResearch and development expenses for the three months ended December 31, 2024, were $4.4 million.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eh\u003c\/strong\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/p\u003e\n\u003cp\u003eThis core belief drives the entire R\u0026amp;D and clinical strategy, from the Phase III design to the confirmatory study protocol.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003ePeriod\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eConfirmatory Study Enrollment Target\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e212\u003c\/strong\u003e patients\u003c\/td\u003e\n\u003ctd\u003eRegistration Study\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e5-Year OS Hazard Ratio (Target Population)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0.35\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePhase 3 Study (Target Population)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expenses\u003c\/td\u003e\n\u003ctd\u003eApprox. \u003cstrong\u003e$9 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eSix months ended March 31, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eThree months ended December 31, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eh\u003c\/strong\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003c\/p\u003e\n\u003cp\u003eTemporary. The knowledge itself is not proprietary, but its successful application in Multikine is what matters.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\nThe target patient population for the confirmatory study represents about 40% of all advanced primary head and neck cancer cases annually.\n\u003c\/li\u003e\n\u003cli\u003e\nThe Phase 3 study showed a statistically significant (p=0.0236, HR=0.68) overall survival benefit of 14.1% at 5 years in the group receiving Multikine plus surgery and radiotherapy, but not chemotherapy.\n\u003c\/li\u003e\n\u003cli\u003e\nThe company has Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eCEL-SCI Corporation (CVM) - VRIO Analysis: \u003cstrong\u003e9. Operational Footprint in the US\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Maintains operations in Vienna, Virginia, and near Baltimore, Maryland, providing a physical base for US regulatory interaction and potential future commercial activities. The Baltimore facility was designed to comprise \u003cstrong\u003e73,000 square feet\u003c\/strong\u003e for Multikine manufacturing.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Having established, FDA-facing facilities is a baseline requirement, but it’s a necessary resource for a US-listed company. The company completed a \u003cstrong\u003e928 patient\u003c\/strong\u003e Phase 3 clinical trial in the US and globally.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low. Physical locations are easily imitable, though the established relationships are not.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e This physical presence supports the ongoing dialogue with the FDA regarding the confirmatory study protocol. The headquarters is located in Vienna, Virginia.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e None. This is a necessary, but not differentiating, resource.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eFinance:\u003c\/strong\u003e Draft 13-week cash view incorporating the \u003cstrong\u003e$10 million\u003c\/strong\u003e offering closed in August 2025 by Friday, August 29, 2025. The offering generated gross proceeds of approximately \u003cstrong\u003e$10 million\u003c\/strong\u003e from the sale of 1,111,200 shares at \u003cstrong\u003e$9.00\u003c\/strong\u003e per share.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eWeek 1\u003c\/td\u003e\n\u003ctd\u003eWeek 5\u003c\/td\u003e\n\u003ctd\u003eWeek 13\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eStarting Cash Balance (Post-Closing)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$11,790,000.00\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$6,430,000.00\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$-4,170,000.00\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCumulative Cash From Operations (Burn Proxy)\u003c\/td\u003e\n\u003ctd\u003e$-1,330,000.00\u003c\/td\u003e\n\u003ctd\u003e$-6,650,000.00\u003c\/td\u003e\n\u003ctd\u003e$-17,270,000.00\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCumulative Cash From Financing (Aug 2025 Close)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10,000,000.00\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10,000,000.00\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10,000,000.00\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe cash balance projection above uses the \u003cstrong\u003e$10,000,000.00\u003c\/strong\u003e financing inflow and a projected weekly operating cash burn rate of approximately \u003cstrong\u003e$1,330,000.00\u003c\/strong\u003e, derived from the reported Cash From Operating Activities of \u003cstrong\u003e$-17,270,000.00\u003c\/strong\u003e for the quarter.\u003c\/p\u003e\n\u003cp\u003eOther relevant financial and operational data points include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eGross proceeds from the July 2025 offering: approximately \u003cstrong\u003e$5.7 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eGross proceeds from the May 2025 offering: \u003cstrong\u003e$5 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash balance as of a recent reporting period: \u003cstrong\u003e$1.79 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePre-Tax Income for a recent period: \u003cstrong\u003e$-25.61 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet Income for a recent period: \u003cstrong\u003e$-25.42 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash From Financing Activities for a recent period: \u003cstrong\u003e$18.73 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eMultikine manufacturing plant capacity: estimated to make \u003cstrong\u003e$2 billion\u003c\/strong\u003e worth of Multikine annually.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516147130517,"sku":"cvm-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/cvm-vrio-analysis.png?v=1740158359","url":"https:\/\/dcf-model.com\/fr\/products\/cvm-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}